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Background: Human immunodeficiency virus (HIV) is a global health concern with major risks for opportunistic 
infections and predisposition to malignancies including Kaposi sarcoma associated with Human Herpes Virus-8 (HHV-
8) and non-Hodgkin lymphoma (NHL) commonly associated with Epstein Barr Virus (EBV). Although the exact 
mechanisms of predisposition to certain malignancies are unclear, HIV (+) cancer patients typically have poorer 
prognosis.  
Materials and Methods: We included all five HIV positive NHL patients receiving antiretroviral therapy (ART) and 
chemotherapy in our clinic and aim to determine their follow-up outcomes associated with ART. 
Results: The use of ART in conjunction with chemotherapy regimens lead to better therapeutic outcome in our cases 
with no mortality over three years of follow-up despite high rates of poor prognostic factors and studies demonstrating 
1-year survival rates of approximately 30% in HIV-associated lymphoma. No significant adverse effect has been 
recorded. 
Conclusion: We recommend use of ART along with chemotherapy regimens in HIV positive lymphoma patients for 
better treatment response.  
 
Keywords: Human immunodeficiency virus, lymphoma, non-Hodgkin lymphoma, anti-retroviral therapy. 
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EBV-Epstein Barr Virus, NHL-Non-Hodgkin lymphoma, DLBCL- Diffuse large B-cell lymphoma, CD-Cluster of 
differentiation, R-CHOP- Rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone, GDP-Gemcitabine-
dexamethasone-cisplatin, R-DHAP-Rituximab-cisplatin-cytosine arabinoside-dexamethasone, DA-EPOCH-Dose-
adjusted etoposide-vincristine-doxorubicin-oral prednisolone-dose-escalated cyclophosphamide, PET-Positron 
emission tomography, FDG-Fluorodeoxyglucose, CT-Computed tomography, MRI-Magnetic resonance imaging, 
SUVmax-Maximal measuring standardized uptake value, FISH-Fluorescence in situ hybridization, VDRL-Venereal 
Disease Research Laboratory, ECOG- The Eastern Cooperative Oncology Group, IPI- The International Prognostic 




 Human immunodeficiency virus (HIV) is a predisposing factor for certain malignancies including lymphoma. 
Despite high incidence of concomitant infections with Human Herpes Virus-8 (HHV-8) and Epstein Barr Virus (EBV), 
primary mechanism underlying malignant transformation is thought to be HIV-related immunosuppression (Grulich et 
al., 2007). Possible hypothesis include increased apoptotic rates in lymphocytes, defects at natural killer cells, 
hypergammaglobulinemia and over-proliferation of T-cells at lymph nodes (Haas et al., 2011). In addition to being a 
predisposing factor for malignancy, HIV-infection is a poor prognostic factor after malignant transformation in terms of 
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both of which are independent poor prognostic factors, a retrospective study conducted with forty-nine HIV positive 
Burkitt lymphoma patients (Opie et al., 2020). However, HIV viral load was not associated with mortality in a study 
conducted with eighty-six participants in Sub-Saharan Africa (Painschab et al., 2019).  25-40% of HIV-infected 
population has shown to develop malignancy in their life-time while Kaposi sarcoma, cervical cancer and non-Hodgkin 
lymphoma (NHL) are the most common HIV-associated malignancies. 20% of HIV-infected patients develop NHL 
during life-time, while 2-3% of those are diagnosed with NHL at the time of HIV diagnosis (Grulich et al., 2007; 
Rabkin  and Yellin 1994). Most predominant subtype of NHL is diffuse large B-cell lymphoma (DLBCL) composing 
75% of the cases followed by Burkitt lymphoma (Rabkin  and Yellin 1994). NHL incidence was 25-100 fold higher in 
HIV-infected population before the use of ART, while malignancies remain the most common cause of mortality in 
developed countries despite the use of ART (Smith et al., 2014). In this study we report five cases of HIV-infected 





 A 77-year-old male patient presented to our clinic with multiple palpable cervical, axillary, mediastinal and 
abdominal lymph nodes. Computed tomography studies revealed multiple abdominal and thoracic lymph nodes (largest 
being 18.0×9.5 mm at left mediastinum) and splenic infiltrative lesion at 31×32 mm size. Excisional lymph node 
biopsy specimen was suggestive of DLBCL. The clinical stage was III and the patient was started on combination 
chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) and involved field 
radiotherapy (17 cycles with total of 30.6 Gray). Bone marrow biopsy was not suggestive of lymphoma. The disease 
recurred after 3 years in which the patient presented with progressive cervical lymphadenomegaly. Meanwhile, the 
patient was positive for anti-HIV test. Anti-viral therapy and simultaneous chemotherapy with rituximab and 
bendamustine regimen due to the comorbidities of patient were initiated (Table 1). Due to lack of efficient 
chemotherapeutic response, chemotherapy regimen was switched to gemcitabine, dexamethasone, cisplatin (GDP) for 
which patient developed intolerance. Lenalidomide was administered which was then switched to rituximab, cisplatin, 
cytosine arabinoside, dexamethasone (R-DHAP) and involved field radiotherapy due to lack of adequate therapeutic 




 A 30-year-old male patient presented to our clinic with the diagnosis of high grade diffuse large B-cell 
lymphoma/Burkitt lymphoma after excisional biopsy of cervical lymphadenomegaly. He was found to be HIV positive 
during initial laboratory work-up. Bone marrow biopsy showed no lymphoma involvement. Positron emission 
tomography (PET)-CT scan revealed left cervical, bilateral axillary, lymph nodes located inferior to left parathyroid 
gland and bilateral nasopharyngeal involvement. The clinical stage was II and the patient was started on combination 
chemotherapy with R-CHOP simultaneously with the anti-viral therapy (Table 1). Follow-up of patient has been 




 A 63-year-old male patient presented to internal medicine policlinic with a year history of fatigue, fever and 
dyspnea on exertion. HIV RNA test previously performed in another center was positive. The patient had been 
followed up and anti-viral therapy was initiated (Table 1). PET scan (Fig 1a-b) performed upon persistent fever on 2-
month follow-up revealed infiltrative lesions on spleen, a lesion with 3 cm diameter (SUVmax=13.5) and another 
lesion with 75 mm diameter (SUVmax=5.0), for which tru-cut biopsy was obtained, and bilateral lesions at thalamus 
and basal ganglion (SUVmax=7.8). Pathological examination of specimen indicated DLBCL (Fig 1c-d).  Patient 
developed headache for which brain MRI was planned revealing involvement of thalamus, whereas, cerebrospinal fluid 
was free of pathology. Patient had received 6 cycles of R-CHOP regimen and intrathecal methotrexate/cytarabine 
chemotherapy after being considered as stage IV DLBCL. Treatment led to complete metabolic response of cervical 
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R-CHOP IPI 2 
Stage II 
ECOG 1 











DLBCL Bcl-2 (-) 
Bcl-6 (-) 
c-myc (+) 
R-CHOP IPI 1 







Figure 1: PET-CT of the case 3 demonstrates bilateral thalamus and basal ganglion lesion and splenic lesions with high 
fluorodeoxyglucose (FDG) uptake (1a/b) while biopsy samples of the same patient demonstrate centroblastic lymphoid 




 A 43-year-old HIV (+) male patient presented with nasal congestion and fever to ear, nose and throat (ENT) 
specialist. Biopsy obtained from non-regressing lesion at left maxillary sinus revealed DLBCL while laboratory work-
up showed positivity for EBV at that time. Past medical history of the patient was significant for eczema with 
exanthematous skin lesions and VDRL positivity treated with penicillin. Further evaluation demonstrated CD4 cell 
count of 21 cells/μL. Anti-viral therapy and 6 cycles of R-CHOP regimen were initiated. Following 6 cycles of 
chemotherapy complete metabolic response was achieved. Later on, patient presented to our clinic with nasal 
congestion during which biopsy obtained from right maxillary sinus revealed 10×7×2 mm soft irregular mass 
containing malignant kappa light chain plasma cell infiltration with CD38 positivity and lambda negativity considered 
as plasmacytoma. Bone marrow biopsy was obtained by the differential diagnosis of multiple myeloma demonstrated 
normocellular bone marrow without any atypia. Patient received radiotherapy for plasmacytoma. Follow-up of the 




 A 33-year-old HIV (+) male patient with undetectable HIV RNA over 3 months was admitted to our clinic 
with bulky neck mass. MRI revealed an irregular 63×47×80 mm mass located posterior to sternocleidomastoid muscle 
after which PET scan demonstrated hypermetabolic profile of the cervical mass in addition to suspicious 
hypermetabolic lesions at spleen and adrenal gland. Patient described the absence of B-symptoms. Past medical history 
was significant for tonsillectomy and surgically-resected anal condyloma while family history was significant for 
hepatocellular carcinoma in father. Biopsy revealed germinal center DLBCL with positivity for Bcl-6 and c-myc, 
however, FISH analysis ruled out c-myc and Bcl-6 positivity. Patient received 2 cycles of R-CHOP regimen which was 




 HIV infection is a strong predisposing factor for malignant transformation, therefore, high risk patients 
presenting with advanced staged NHL or fast disease progression should be checked for concomitant HIV infection. 
Poor prognostic factors include low CD4 cell count (< 100 cells/ml), high LDH values, IV drug abuse, advanced stage 




factors, while all patients received ART (Table 1). In addition, our patients also suffer from comorbidities including 
eczema, hepatitis B virus (HBV) and EBV infections and syphilis. Only a single cohort including 1872 HIV-infected 
patients with malignancy rate of 2.6% has been performed in Turkish population (Aydin et al., 2020). Therefore, our 
study is significant by demonstrating beneficial effects of HIV-related lymphoma cases in Turkey that received ART in 
addition to chemotherapy regimens.  
 Two commonly preferred chemotherapy regimens for HIV-related NHL cases are R-CHOP and dose-adjusted 
etoposide-vincristine-doxorubicin-oral prednisolone-dose-escalated cyclophosphamide (DA-EPOCH), while choice 
should be individualized. DA-EPOCH is recommended in CD20 (+) patients with plasmablastic histology or high 
growth fraction disease (Ki67>80%) unless CD4 cell count is below 50 cells/ml while none were present in our study 
population (Little et al., 2003). Combination of rituximab and DA-EPOCH therapy should be considered in cases with 
poor prognostic factors, though, results of clinical trials are inconclusive (Dunleavy et al., 2010; Sparano et al., 2010).  
Combination therapy with ART and chemotherapy leads to decline in HIV RNA levels and elevation at CD4 cell count 
in our cases. Declining viral load may be the underlying mechanism of beneficial effects of ART (Tirelli  and Bernardi, 
2001). No significant adverse effects of ART have been detected in our cases.  
 Another feature of HIV-associated lymphoma is the atypical presentation sites. Similarly, one of our cases 
presented with maxillary sinus involvement, while only limited number of cases with maxillary sinus lymphoma were 
present (Basavaraj et al., 2016). Moreover, most HIV-associated lymphoma cases reported in maxillary sinus have 
been reported as plasmablastic lymphoma in contrast to our case presenting with DLBCL. 
 Despite studies indicating 1-year survival rate of 30% in HIV-associated lymphoma, individualized treatment 
modalities involving multidisciplinary approach have led to uneventful follow-up of all cases with HIV-associated 
lymphoma in our clinic for the last 3 years (Yancheva et al., 2018). We assume that therapeutic outcomes of HIV (+) 
patients presenting with NHL might improve in the upcoming years with the improvements in ART options.  Thus, we 
strongly suggest utilization of ART combined with chemotherapy in HIV-positive patients presenting with lymphoma 
to improve therapeutic outcomes.  
 
Compliance with Ethical Standards: Ethical guidelines of Turkey were followed. 
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